% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Hansen:281871,
      author       = {Hansen, Niels and Wiltfang, Jens},
      title        = {{K}rankheitsmodifizierende {T}herapie mit {L}ecanemab bei
                      früher {A}lzheimer-{D}emenz | {D}isease-modifying therapy
                      with lecanemab for early {A}lzheimer's dementia},
      journal      = {Fortschritte der Neurologie, Psychiatrie},
      volume       = {93},
      number       = {11},
      issn         = {0720-4299},
      address      = {Stuttgart [u.a.]},
      publisher    = {Thieme},
      reportid     = {DZNE-2025-01242},
      pages        = {453 - 460},
      year         = {2025},
      abstract     = {Alzheimer's disease (AD) is a severe and progressive
                      neurodegenerative disease of the brain that has so far been
                      treated with symptomatic drug and non-drug therapies as
                      standard treatment. Following the approval of the monoclonal
                      anti-amyloid antibody by the FDA, AD therapy has changed, as
                      this therapy has made it possible to attenuate the
                      biological disease process of AD. Lecanemab has been
                      recommended by the Committee for Medicinal Products for
                      Human Use (CHMP) of the European Medicines Agency (EMA) for
                      approval in patients with early AD under two conditions.
                      Firstly, homozygous ApoE4 carriers and secondly, patients
                      receiving oral anticoagulants should not receive lecanemab.
                      The following narrative review explains the mechanism of
                      action, safety and side effects of lecanemab. Furthermore,
                      risk factors for side effects are described. Finally, the
                      first experiences with lecanemab are reported and the
                      efficacy and financial aspects are discussed. Lecanemab
                      leads to a temporary reduction in amyloid-ß deposits and to
                      a benefit that can be reflected in everyday competence,
                      cognition and quality of life and can be described as a
                      breakthrough in AD's therapy due to its demonstrable
                      biological and clinical efficacy.},
      subtyp        = {Review Article},
      keywords     = {Humans / Alzheimer Disease: drug therapy / Alzheimer
                      Disease: psychology / Antibodies, Monoclonal, Humanized:
                      therapeutic use / Antibodies, Monoclonal, Humanized: adverse
                      effects / Amyloid beta-Peptides: metabolism / Antibodies,
                      Monoclonal, Humanized (NLM Chemicals) / Amyloid
                      beta-Peptides (NLM Chemicals)},
      cin          = {AG Wiltfang},
      ddc          = {150},
      cid          = {I:(DE-2719)1410006},
      pnm          = {353 - Clinical and Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-353},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:41052542},
      pmc          = {pmc:PMC12591830},
      doi          = {10.1055/a-2681-4558},
      url          = {https://pub.dzne.de/record/281871},
}